Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.
Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
Pediatr Transplant. 2024 Sep;28(6):e14838. doi: 10.1111/petr.14838.
Although the outcomes of living donor liver transplantation (LDLT) for pediatric acute liver failure (PALF) have improved, patient survival remains lower than in patients with chronic liver disease. We investigated whether the poor outcomes of LDLT for PALF persisted in the contemporary transplant era.
We analyzed 193 patients who underwent LDLT between December 2000 and December 2020. The outcomes of patients managed in 2000-2010 (era 1) and 2011-2020 (era 2) were compared.
The median age at the time of LDLT was 1.2 years both eras. An unknown etiology was the major cause in both groups. Patients in era 1 were more likely to have surgical complications, including hepatic artery and biliary complications (p = 0.001 and p = 0.013, respectively). The era had no impact on the infection rate after LDLT (cytomegalovirus, Epstein-Barr virus, and sepsis). The mortality rates of patients and grafts in era one were significantly higher (p = 0.03 and p = 0.047, respectively). The 1- and 5-year survival rates were 76.4% and 70.9%, respectively, in era 1, while they were 88.3% and 81.9% in era 2 (p = 0.042). Rejection was the most common cause of graft loss in both groups. In the multivariate analysis, sepsis during the 30 days after LDLT was independently associated with graft loss (p = 0.002).
The survival of patients with PALF has improved in the contemporary transplant era. The early detection and proper management of rejection in patients, while being cautious of sepsis, should be recommended to improve outcomes further.
尽管活体肝移植(LDLT)治疗儿童急性肝衰竭(PALF)的结果有所改善,但患者的存活率仍低于慢性肝病患者。我们研究了在当代移植时代,LDLT 治疗 PALF 的不良结果是否仍然存在。
我们分析了 193 例于 2000 年 12 月至 2020 年 12 月期间接受 LDLT 的患者。比较了 2000-2010 年(时代 1)和 2011-2020 年(时代 2)接受治疗的患者的结局。
LDLT 时的中位年龄在两个时代均为 1.2 岁。未知病因是两个组的主要原因。时代 1 的患者更有可能出现手术并发症,包括肝动脉和胆道并发症(p=0.001 和 p=0.013)。时代对 LDLT 后的感染率(巨细胞病毒、EB 病毒和败血症)没有影响。时代 1 中患者和移植物的死亡率显著更高(p=0.03 和 p=0.047)。时代 1 的 1 年和 5 年生存率分别为 76.4%和 70.9%,而时代 2 分别为 88.3%和 81.9%(p=0.042)。排斥反应是两组中移植物丢失的最常见原因。在多变量分析中,LDLT 后 30 天内的败血症与移植物丢失独立相关(p=0.002)。
在当代移植时代,PALF 患者的生存率有所提高。应建议早期发现和适当管理患者的排斥反应,同时谨慎对待败血症,以进一步改善结局。